论文信息 - [Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma: current evidence]. - 字舞流文

[Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma: current evidence].

C. Bolenz | F. Zengerling

[1] R. Koch,et al. Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019 , 2022, World Journal of Urology.

[2] U. Capitanio,et al. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. , 2021, Urologic oncology.

[3] A. Masson-Lecomte,et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.

[4] V. Margulis,et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma , 2014, Cancer.

[5] F. Montorsi,et al. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades , 2012, International journal of urology : official journal of the Japanese Urological Association.

[6] Y. Lotan,et al. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.